Therapy Areas: Oncology
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
13 July 2026 - Swedish pharmaceutical company Newbury Pharmaceuticals AB (STO:NEWBRY) announced on Monday that it has received marketing authorisation in Sweden for Tofacitinib Newbury 5 mg and 10 mg ...
HDT Bio Launches Canadian clinical programme for brain cancer treatment
13 July 2026 - US-based clinical-stage biotechnology company HDT Bio Corp announced on Sunday the establishment of HDT Bio Canada Inc, its Canadian subsidiary, formed to advance its cancer immunothera...
Accord BioPharma's second pegfilgrastim biosimilar to NEULASTA approved by US FDA
10 July 2026 - Accord BioPharma, the US specialty division of India-based Intas Pharmaceuticals Ltd, focused on the development of oncology, immunology, and central nervous system (CNS) therapies, ann...
BiBBInstruments signs first European distribution deal for EndoDrill GI with Palex Spain
10 July 2026 - Swedish cancer diagnostics company BiBBInstruments AB (Spotlight Stock Market: BIBB) said on Thursday it has signed its first European commercial distribution agreement for its powered ...
Northwest Biotherapeutics presents updated DCVax-L Phase III trial survival data for glioblastoma
9 July 2026 - Northwest Biotherapeutics (OTCQB:NWBO)(NWBio), a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers, announced on Wednesday that the company�...
HanchorBio plans combination research with late-stage cancer drug resistance specialist InxMed
9 July 2026 - Taiwan-listed clinical-stage biotech HanchorBio Inc (TWSE:7827) announced on Wednesday that it is looking to broaden the development path for HCB101, its lead oncology asset, through a n...